摘要
目的探讨参麦注射液联合盐酸氟桂利嗪治疗脑梗死后血管性痴呆的临床价值。方法选择2014年1月至2015年1月收治的脑梗死后血管性痴呆患者90例,随机将其分为对照组与观察组,每组45例,对照组给予盐酸氟桂利嗪胶囊治疗,观察组采用中西医结合的方式,即在对照组治疗基础上给予参麦注射液,比较两组患者PANSS总分及IMCT的变化,评价患者症状改善情况。结果两组治疗后PANSS总分及IMCT均较治疗前有显著改善(P<0.05),且观察组较对照组改善更为明显(P<0.05);观察组症状改善程度明显优于对照组(P均<0.05)。结论参麦注射液联合盐酸氟桂利嗪治疗脑梗死后血管性痴呆可显著改善其临床症状,提高患者的社会适用力、智力及记忆力水平。
Objective To investigate the clinical value of Shenmai injection combined with flunarizine hydrochloride capsules on vascular dementia after cerebral infarction. Methods Ninety patients with cerebral infarction vascular dementia were random- ly divided into observation group and control group with 45 cases in each group. The control group was given fltmarizine hydro- chloride capsules for treatment and the observation group was given Shenmai injection on the basis of the control group; the thera- peutic effects of the two groups were compared. The change of the total scores of PANSS and IMCT of the two groups were com- pared, and the situation of improving symptoms was evaluated. Results The total score of PANSS and IMCT in the two groups after treatment had improved significantly compared with that before treatment （P 〈 0.05 ）. But the observation group was more significant than the control group （P 〈 0. 05 ）, the symptoms of the observation group were significantly better than those of the control group （ P 〈 0. 05 ）. Conclusion Shenmai injection combined with flunarizine hydrochloride capsules in the treatment of vascular dementia after cerebral infarction can significantly improve the clinical symptoms, improve patients with social and appli- cable power and intelligence and memory level of patients.
出处
《临床医学》
CAS
2016年第6期11-13,共3页
Clinical Medicine
关键词
血管性痴呆
参麦注射液
盐酸氟桂利嗪胶囊
Vascular dementia
Shenmai injection
Flunarizine hydrochloride capsule
